Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Inclusion Criteria:

* Men or women aged more than or equal to (≥) 18 years.
* Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is failed or intolerable.
* Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required). Patients with only brain and/or bone lesions as target lesions will not be included.
* Fresh or archived tumor tissue samples need to be provided (fresh samples are preferred, and tumor tissue samples within 2 years before the first administration can be accepted; the sample type is formalin fixed, paraffin embedded \[FFPE\] tumor tissue block or FFPE slides).
* ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks.
* Estimated life expectancy greater than (\>) 12 weeks.
* Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
* Females must have the evidence of non-childbearing potential.
* Sign informed consent form.

Exclusion Criteria:

* Has received or is currently undergoing the following treatment:

  1. Previously or current treatment with drugs targeting Trop-2 or other ADC drugs conjugated with HS-9265;
  2. Received traditional Chinese medicine therapy with anti-tumor indications within 2 weeks prior to the first administration of HS-20105;
  3. Received cytotoxic chemotherapy drugs or other anti-tumor system therapies (including endocrine therapy, molecular targeted therapy, or biological therapy) within 3 weeks prior to the first administration of HS-20105;
  4. Received macromolecular anti-tumor drugs or experimental drug therapy within 4 weeks before the first administration of HS-20105;
  5. Received local radiotherapy within 2 weeks before the first administration of HS-20105; Received more than 30% of bone marrow irradiation or extensive radiation therapy within 4 weeks before the first administration of HS-20105;
  6. Received major surgery within 4 weeks before the first administration of HS-20105.
  7. Received strong inhibitors or inducers of CYP3A4, CYP2D6, P-gp or BCRP, or drugs with narrow treatment windows for CYP3A4, CYP2D6, P-gp or BCRP sensitive substrates, have been used.
  8. Receiving medication that is known to prolong the QT interval or may lead to torsade de pointes.
* Existing abnormal CTCAE ≥ grade 2 resulted from previous treatment.
* History of other malignancy.
* Uncontrolled pleural, ascites or pericardial effusion.
* Known and unstable central nervous system metastases.
* Inadequate bone marrow reserve or serious organ dysfunction.
* Severe, uncontrolled, or active cardiovascular disease.
* Severe or poorly controlled diabetes.
* Severe or poorly controlled hypertension.
* Clinically significant bleeding symptoms within 1 month before the first administration of HS-20105.
* Serious thrombosis events within 3 months before the first administration of HS-20105.
* Serious infection within 4 weeks before the first administration of HS-20105.
* Received continuous glucocorticoid treatment for more than 7 days within 28 days before the first administration of HS-20105.
* Active infectious disease.
* Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child-Pugh B-grade cirrhosis.
* Serious or uncontrolled eye disease.
* Moderate to severe lung diseases that may interfere with the detection or management of drug-related pulmonary toxicity and seriously affect respiratory function.
* Severe neurological or mental disorders that can interfere with assessment.
* Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
* History of hypersensitivity to any active or inactive ingredient of HS-20105.
* The subject who is unlikely to comply with study procedures, restrictions, or requirements, judged by the investigator
* The subject whose safety cannot be ensured or study assessments would be interfered, judged by the investigator.